Caladrius Biosciences Announces NIH Grant to Fund Retinal Disease Research

By: via Benzinga
Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ: CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.